<p>关注 <strong>Eupraxia Pharmaceuticals Inc.</strong> (TSE:EPRX) 的人无疑会对公司独立董事 Joseph Freedman 最近购买股票的消息感到好奇，他以平均每股 CA$7.64 的价格花费了高达 CA$1.8 百万购买股票。这不仅是一个巨大的举动，还使他们的持股增加了 13%，这无疑是令人欣慰的。</p>
<p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
<h2>Eupraxia Pharmaceuticals 最近 12 个月的内部交易</h2>
<p>事实上，根据我们的记录，Joseph Freedman 最近的购买是过去 12 个月内内部人士对 Eupraxia Pharmaceuticals 股票的最大购买。因此，很明显，有内部人士希望在当前价格（CA$7.99 左右）附近进行购买。当然，他们可能改变了主意。但这表明他们持乐观态度。我们总是喜欢看到内部人士的购买，但值得注意的是，如果这些购买是在远低于今天的股价时进行的，因为随着价格上涨，价值折扣可能已经缩小。令人欣慰的是，Eupraxia Pharmaceuticals 的内部人士决定在接近当前价格时购买股票。</p>
<p>虽然 Eupraxia Pharmaceuticals 的内部人士在过去一年中购买了股票，但他们并没有出售。您可以在下面的图表中看到过去一年内（公司和个人）的内部交易。如果您想确切知道是谁出售的、出售了多少以及何时出售，只需点击下面的图表！</p>
<p>查看我们对 Eupraxia Pharmaceuticals 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/225412256-insider-trading-volume-1-dark-2/1759064042331?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/225412256-insider-trading-volume-1-dark-2/1759064042331"/></p>
<p>TSX:EPRX 内部交易量 2025 年 9 月 28 日</p>
<p>还有很多其他公司也有内部人士购买股票。您可能不想错过这份 <strong>免费</strong> 的被低估小型公司的名单，内部人士正在购买。</p>
<h2>内部持股</h2>
<p>对于普通股东来说，检查公司内部人士持有多少股票是值得的。通常，内部持股越高，内部人士更有可能被激励长期发展公司。看起来 Eupraxia Pharmaceuticals 的内部人士拥有公司 18% 的股份，价值约 CA$7000 万。我们确实在其他地方看到过更高的内部持股水平，但这些持股足以表明内部人士与其他股东之间的利益一致。</p>
<h2>Eupraxia Pharmaceuticals 的内部交易可能告诉我们什么？</h2>
<p>看到最近的购买是件好事。对过去一年交易的分析也给了我们信心。但另一方面，公司在过去一年中亏损，这让我们有些谨慎。考虑到内部人士也拥有相当多的 Eupraxia Pharmaceuticals 股票，我们认为他们可能对光明的未来相当有信心。除了了解内部交易外，识别 Eupraxia Pharmaceuticals 面临的风险也是有益的。例如，Eupraxia Pharmaceuticals 有 <strong>3 个警告信号</strong>（其中 2 个不容忽视），我们认为您应该了解。</p>
<p>如果您更愿意查看另一家公司——一家财务状况可能更优越的公司——那么不要错过这份 <strong>免费</strong> 的有趣公司名单，这些公司具有高股本回报率和低债务。</p>
<p><em>在本文中，内部人士是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置，但不包括衍生交易或间接利益。</em></p>

EPRX

<p>Eupraxia Pharmaceuticals 的独立董事 Joseph Freedman 额外购买了 13% 的股份，投资金额为 180 万加元，平均价格为 7.64 加元。这是过去一年中最大的内部人士购买，表明对公司未来的乐观态度。尽管去年出现亏损，但内部人士持有公司 18% 的股份，表明与股东利益的一致性。在过去一年中没有发生内部人士出售，进一步增强了对公司前景的信心，尽管由于存在警示信号，仍需保持谨慎</p>

<p>Those following along with <strong>Eupraxia Pharmaceuticals Inc.</strong> (TSE:EPRX) will no doubt be intrigued by the recent purchase of shares by Joseph Freedman, Independent Director of the company, who spent a stonking CA$1.8m on stock at an average price of CA$7.64. Not only is that a big swing, but it increased their holding size by 13%, which is definitely great to see.</p>
<div class="lb-trans"><p>关注 <strong>Eupraxia Pharmaceuticals Inc.</strong> (TSE:EPRX) 的人无疑会对公司独立董事 Joseph Freedman 最近购买股票的消息感到好奇，他以平均每股 CA$7.64 的价格花费了高达 CA$1.8 百万购买股票。这不仅是一个巨大的举动，还使他们的持股增加了 13%，这无疑是令人欣慰的。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 21 只美国股票预计明年将支付超过 6% 的股息收益率。查看完整列表，免费获取。</p>
</div><h2>The Last 12 Months Of Insider Transactions At Eupraxia Pharmaceuticals</h2>
<div class="lb-trans"><h2>Eupraxia Pharmaceuticals 最近 12 个月的内部交易</h2>
</div><p>In fact, the recent purchase by Joseph Freedman was the biggest purchase of Eupraxia Pharmaceuticals shares made by an insider individual in the last twelve months, according to our records. So it's clear an insider wanted to buy, at around the current price, which is CA$7.99. Of course they may have changed their mind. But this suggests they are optimistic. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Eupraxia Pharmaceuticals insiders decided to buy shares at close to current prices.</p>
<div class="lb-trans"><p>事实上，根据我们的记录，Joseph Freedman 最近的购买是过去 12 个月内内部人士对 Eupraxia Pharmaceuticals 股票的最大购买。因此，很明显，有内部人士希望在当前价格（CA$7.99 左右）附近进行购买。当然，他们可能改变了主意。但这表明他们持乐观态度。我们总是喜欢看到内部人士的购买，但值得注意的是，如果这些购买是在远低于今天的股价时进行的，因为随着价格上涨，价值折扣可能已经缩小。令人欣慰的是，Eupraxia Pharmaceuticals 的内部人士决定在接近当前价格时购买股票。</p>
</div><p>While Eupraxia Pharmaceuticals insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!</p>
<div class="lb-trans"><p>虽然 Eupraxia Pharmaceuticals 的内部人士在过去一年中购买了股票，但他们并没有出售。您可以在下面的图表中看到过去一年内（公司和个人）的内部交易。如果您想确切知道是谁出售的、出售了多少以及何时出售，只需点击下面的图表！</p>
</div><p>See our latest analysis for Eupraxia Pharmaceuticals</p>
<div class="lb-trans"><p>查看我们对 Eupraxia Pharmaceuticals 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/225412256-insider-trading-volume-1-dark-2/1759064042331" alt="" original-src="https://images.simplywall.st/asset/chart/225412256-insider-trading-volume-1-dark-2/1759064042331"/></p>
<p>TSX:EPRX Insider Trading Volume September 28th 2025</p>
<div class="lb-trans"><p>TSX:EPRX 内部交易量 2025 年 9 月 28 日</p>
</div><p>There are plenty of other companies that have insiders buying up shares. You probably do <strong>not</strong> want to miss this <strong>free</strong> list of undervalued small cap companies that insiders are buying.</p>
<div class="lb-trans"><p>还有很多其他公司也有内部人士购买股票。您可能不想错过这份 <strong>免费</strong> 的被低估小型公司的名单，内部人士正在购买。</p>
</div><h2>Insider Ownership</h2>
<div class="lb-trans"><h2>内部持股</h2>
</div><p>For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that Eupraxia Pharmaceuticals insiders own 18% of the company, worth about CA$70m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.</p>
<div class="lb-trans"><p>对于普通股东来说，检查公司内部人士持有多少股票是值得的。通常，内部持股越高，内部人士更有可能被激励长期发展公司。看起来 Eupraxia Pharmaceuticals 的内部人士拥有公司 18% 的股份，价值约 CA$7000 万。我们确实在其他地方看到过更高的内部持股水平，但这些持股足以表明内部人士与其他股东之间的利益一致。</p>
</div><h2>What Might The Insider Transactions At Eupraxia Pharmaceuticals Tell Us?</h2>
<div class="lb-trans"><h2>Eupraxia Pharmaceuticals 的内部交易可能告诉我们什么？</h2>
</div><p>It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of Eupraxia Pharmaceuticals we think they are probably pretty confident of a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Eupraxia Pharmaceuticals. For example, Eupraxia Pharmaceuticals has <strong>3 warning signs</strong> (and 2 which shouldn't be ignored) we think you should know about.</p>
<div class="lb-trans"><p>看到最近的购买是件好事。对过去一年交易的分析也给了我们信心。但另一方面，公司在过去一年中亏损，这让我们有些谨慎。考虑到内部人士也拥有相当多的 Eupraxia Pharmaceuticals 股票，我们认为他们可能对光明的未来相当有信心。除了了解内部交易外，识别 Eupraxia Pharmaceuticals 面临的风险也是有益的。例如，Eupraxia Pharmaceuticals 有 <strong>3 个警告信号</strong>（其中 2 个不容忽视），我们认为您应该了解。</p>
</div><p>If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this <strong>free</strong> list of interesting companies, that have HIGH return on equity and low debt.</p>
<div class="lb-trans"><p>如果您更愿意查看另一家公司——一家财务状况可能更优越的公司——那么不要错过这份 <strong>免费</strong> 的有趣公司名单，这些公司具有高股本回报率和低债务。</p>
</div><p><em>For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.</em></p>
<div class="lb-trans"><p><em>在本文中，内部人士是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置，但不包括衍生交易或间接利益。</em></p>
</div>

Eupraxia Pharmaceuticals 的独立董事 Joseph Freedman 增持了 13% 的股份